After Hours
$
11.16
Change
-0.04 -0.36%
Volume
Volume 30,392
Aug 15, 2022, 7:24 p.m.
Quotes are delayed by 20 min
Today's close
$ 11.21
$ 11.20
Change
-0.01 -0.09%
Day low
Day high
$10.92
$11.28

52 week low
52 week high
$6.78
$11.34

Market cap
$12.49B
Average volume
14.56M
P/E ratio
N/A
Rev. per Employee
$410,182
EPS
-0.95
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on TEVA
-
Teva Pharmaceutical upgraded to buy from neutral at BofA Securities
- Tomi Kilgore
-
AbbVie Stock Slips After Earnings, Charge for Potential Opioid Deal
- Barron's Online
-
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost
- Barron's Online
-
Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement
- Barron's Online
-
Teva to pay $75 mln over 15 years to settle opioid claims from W. Va., plus pay $8 mln in legal fees
- Steve Gelsi
-
Teva settlement with W. Va. also includes $27 mln worth of generic Narcan over 10 years
- Steve Gelsi
-
W. Va. says Teva opioid agreement consistent with previously announced settlements
- Steve Gelsi
-
Teva Pharmaceutical upgraded to neutral from underperform at BofA Securities
- Tomi Kilgore
-
Pfizer to Buy Biohaven Pharmaceuticals for $11.6 Billion
- Barron's Online
-
Teva CEO Sees a Final Opioid Settlement Coming This Year
- Barron's Online
-
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame.
- Barron's Online
-
Teva now sees full-year revenue of $15.4 bln to $16.0 bln vs. prior guidance of $15.6 bln to $16.2 bln
- Ciara Linnane
-
Teva now sees full-year EPS of $2.40 to $2.60, unchanged vs. prior guidance
- Ciara Linnane
-
Teva lowers full-year revenue guidance
- Ciara Linnane
-
Teva Q1 adj. EPS 55 cents; FactSet consensus 53 cents
- Ciara Linnane
-
Teva Q1 revenue $3.661 bln, down 8%; FactSet consensus $3.598 bln
- Ciara Linnane
- Loading more headlines...
Analyst Ratings
-
Analysts Raise Ratings on Teva Stock on Ajovy’s FDA Approval
- MarketRealist.com
-
Why Teva’s Generic EpiPen Contribution Could Be Modest in 2018
- MarketRealist.com
-
Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results
- MarketRealist.com
Other News on TEVA
-
Walgreens Helped Fuel San Francisco Opioid Epidemic, Judge Rules
- Jennifer Calfas
-
Walgreens Helped Fuel San Francisco Opioid Epidemic, Judge Rules
- Jennifer Calfas
-
Drugmaker Endo Says Bankruptcy Likely Imminent
- Alexander Gladstone
-
Miller Opportunity Trust 2Q 2022 Quarterly Investment Review
- Seeking Alpha
-
Why Teva Stock Trounced the Market on Friday
- Motley Fool
-
Is This Rare Berkshire Hathaway Miscue Finally a Buy?
- Motley Fool
-
- Seeking Alpha
-
Teva Q2 Earnings: 5 Reasons Why Shares Rose By 30%
- Seeking Alpha
-
Teva Tries to Put an End to the Opioid Wars
- David Wainer
-
10-Q: TEVA PHARMACEUTICAL INDUSTRIES LTD
- Edgar Online - (EDG = 10Q, 10K)
-
Teva adds a record 22% as 2Q update addresses opioid uncertainty
- Seeking Alpha
- Loading more headlines...
Press Releases on TEVA
-
Teva Pharmaceutical (TEVA) Trading Report
- Stock Traders Daily
-
Thursday's ETF with Unusual Volume: HEFA
- MarketNewsVideo.com
-
How To Trade Invalid Iqfeed Symbol TEVA
- Stock Traders Daily
-
Teva Reports Second Quarter 2022 Financial Results
- BusinessWire - BZX
-
Certara Appoints Rosemary Crane as New Independent Board Member
- GlobeNewswire
-
Teva Pharmaceutical (TEVA) Trading Report
- Stock Traders Daily
-
Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims
- BusinessWire - BZX
-
Trend Tracker for Teva Pharmaceutical TEVA
- Stock Traders Daily
-
Teva Announces Appointment of New Global R&D and Chief Medical Officer
- BusinessWire - BZX
-
Teva Pharmaceutical (TEVA) Trading Report
- Stock Traders Daily
-
Teva Pharmaceutical TEVA Proactive Strategies
- Stock Traders Daily
-
Migraine Treatment Drugs Market Size, Share | Global Report [2028]
- AmericaNewsHour
-
Learn to Evaluate Teva Pharmaceutical (TEVA) using the Charts
- Stock Traders Daily
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com